Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEM for Breast Cancer Staging
NCT05036083Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2021
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Open-label trial, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Accuracy of CEM for Incremental Cancer Detection at 24 months. Started Mar 2021; status: completed.
Beyond the preview
Go deeper on NCT05036083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05036083.